Metastatic NSCLC

14 registered clinical trials studyying Metastatic NSCLC — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC NCT07524257	ImmunityBio, Inc.	Phase 3
Recruiting	Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) NCT07243132	GFPC Investigation	—
Completed	A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Particip NCT06159790	Sandoz	Phase 3
Terminated	Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer NCT05617313	Jeffrey Clarke	Phase 2
Terminated	SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mu NCT05480865	Navire Pharma Inc., a BridgeBio company	Phase 1
Recruiting	Patient's Whole Process Follow-up Management(HOPE-1) NCT05339568	Qianfoshan Hospital	—
Recruiting	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control NCT05255302	Intergroupe Francophone de Cancerologie Thoracique	Phase 2 / Phase 3
Withdrawn	Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients NCT04615884	Lady Davis Institute	N/A
Active Not Recruiting	Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers NCT05091190	Hospices Civils de Lyon	N/A
Unknown	Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC NCT04846452	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Recruiting	Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study NCT04170634	Hospices Civils de Lyon	—
Active Not Recruiting	NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339	Nanobiotix	Phase 1
Terminated	GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC NCT03417882	BrightPath Biotherapeutics	Phase 2
Completed	Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer NCT01438307	University of Alabama at Birmingham	Phase 2